γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation sets out and critically discusses the current clinical and relevant preclinical γδ T cell immunotherapy landscape.In five chapters, field experts discuss the challenges facing γδ T cell oncoimmunotherapy, propose solutions, and map next steps.Particular attention is given to summarizing our understanding of the complex, translationally relevant human γδ T cell biology, the evidence basis for designing γδ T cell combination trials and data-driven perspectives on what is known—and what isn''t—about γδ T cell therapeutic persistence. Various perspectives are provided on how issues of cytotoxic effector function, functional exhaustion, and cytokine addiction can be mitigated using gene engineering.A chapter is dedicated to the systematic review of all γδ T cell immunotherapy trials to date, and the cell therapy products that were used in these trials. The final chapter discusses allograft persistence-enhancement techniques in the context of γδ T cell therapy, covering lymphodepleting chemotherapy and synthetic stealth engineering.γδ T Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation gives an updated and comprehensive insight into the current state of γδT cell immunotherapy, which is of interest to existing translational γδ T cell specialists, the proliferating range of academic scientists and commercial scientists entering the field, as well as clinicians who may encounter γδ T cell immunotherapy in the clinic, or are wishing to familiarize themselves with noncanonical lymphocyte immunotherapy.- Summarizes the cutting edge of oncology-relevant γδ T cell immunobiology- Lays out clinical successes and failures to date- Addresses the possible advantage of combining γδ T cell-based immunotherapy with conventional chemotherapy or checkpoint blockers- Provides an up-to-date and well-rounded discussion of a translationally, commercially, and scientifically relevant field
